Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10Sarcoma 1Gynecologic 1CNS 1

Conditions

Sarcoma, Endometrial Stromal 1Perivascular Epithelioid Cell Neoplasms 1Adenosarcoma of the uterus 1

Interventions

Radiotherapy 216Cyclophosphamide 211Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 79Irinotecan 79pembrolizumab 75Radiation 67Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 45Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × RAD1901 × Sarcoma × Clear all
NCT07467772 2026-05-22

Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana-Farber Cancer Institute

Phase 2 Recruiting
30 enrolled
GynecologicSarcoma

Adenosarcoma of the uterus, Sarcoma, Endometrial Stromal, Perivascular Epithelioid Cell Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡